Download the Case Study

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform.

In this bispecific case study, learn how the platform:

  • Captured donor-specific responses and their impact on efficacy and safety profiles
  • Identified potential toxicity risks
  • Correlated cytokine release and tumour growth inhibition in the context of bispecifics

Seize this opportunity to gain valuable insights into the future of efficient preclinical drug discovery and development.